|
|
|
|
How to brush your pet's teeth (PDF)
By6r‰##e 7/?8]x (oM$a †F 0X ' QD aR„B 'bQ1‡H!!'S2!.f$e^%Tjjm?j ‡fk,)<wEFn.(.hHI-11e)%†y [bK^Kh62-)R5v„'„4 #hn* &†&cA@a6(PL†0-c •f''p6 ...
|
|
|
Life Sciences: New life sciences study findings have been reported from Korea Research Institute of Bioscience and Biotechnology
Today's Medical & Research News Life Sciences New life sciences study findings have been reported from Korea Research Institute of Bioscience and Biotechnology February 4th, 2010 Printer-Friendly Version Country:South Korea Life Sciences Therapy Treatment...
|
|
|
NeuroSearch announces positive top-line results from Phase III Huntexil study in Huntington's disease (the Mer
- Huntexil significantly improves motor functions in Huntington patients - Positive effects observed on both voluntary and involuntary motor symptoms - Huntexil was very well tolerated with an adverse event profile similar to placebo Copenhagen, 3 February 2010...
|
|
|
Neurosearch A/S (NEUR.CO) Announces Positive Top-line Results from Phase III Huntexil(R) Study in Huntington's
- Huntexil significantly improves motor functions in Huntington patients - Positive effects observed on both voluntary and involuntary motor symptoms - Huntexil was very well tolerated with an adverse event profile similar to placebo Copenhagen, 3 February 2010...
|
|
|
Neurosearch A/S (DK:NEUR) Announces Positive Top-line Results from Phase III Huntexil(R) Study in Huntington's
- Huntexil significantly improves motor functions in Huntington patients - Positive effects observed on both voluntary and involuntary motor symptoms - Huntexil was very well tolerated with an adverse event profile similar to placebo Copenhagen, 3 February 2010...
|
|
|
NeuroSearch Announces Positive Top-line Results From Phase III Huntexil(R) Study in Huntington's Disease (the MermaiHD
Study) -- Huntexil(R) significantly improves motor functions in Huntington patients -- Positive effects observed on both voluntary and involuntary motor symptoms -- Huntexil(R) was very well tolerated with an adverse event profile similar to placebo COPENHAGEN...
|
|
|
NeuroSearch announces positive top-line results from Phase III Huntexil study in Huntington's disease (the MermaiHD study)
- Huntexil significantly improves motor functions in Huntington patients - Positive effects observed on both voluntary and involuntary motor symptoms - Huntexil was very well tolerated with an adverse event profile similar to Copenhagen, 3 February 2010 -...
|
|
|
New data from Astellas Pharma, Inc. illuminate research in pharmacokinetics
A report, 'Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo...
|
|
|
Pharmacokinetics: New data from Astellas Pharma, Inc. illuminate research in pharmacokinetics
Today's Medical & Research News Pharmacokinetics New data from Astellas Pharma, Inc.illuminate research in pharmacokinetics February 2nd, 2010 Printer-Friendly Version City:Osaka Country:Japan Adjuvant Anesthetic Antianxiety Drug Development Drugs GABA...
|
|
|
Axon Expands in the US
AXON have extended their operations in the US market with the senior appointment of Mario Nacinovich as Managing Director of AXON US.AXON is a specialist healthcare consulting firm and the international healthcare operation of NATIONAL Public Relations, one...
|
|
|
Nilotinib May Best Imatinib in 1st-line Treat
New Orleans-In a large, multinational Phase III study, nilotinib (Tasigna, Novartis) demonstrated compelling superiority to imatinib (Gleevec, Novartis) as first-line therapy for chronic myeloid leukemia (CML).More patients achieved the primary end point of...
|
|
|
Synthesis of ternary CuInS2/ZnS quantum dot bioconjugates and their applications for targeted cancer bioimagin
Ken-Tye Yong, Indrajit Roy, Rui Hu, Hong Ding, Hongxing Cai, Jing Zhu, Xihe Zhang, Earl J.Bergey and Paras N. Prasad This contribution introduces the use of cadmium-free CuInS2 quantum dots (QDs) for targeted and multiplexed optical imaging of tumors...
|
|
|
Scientists at University of Munich describe research in molecular therapy
- (Rx.com) 'The knowledge of the biodistribution of macromolecular drug formulations is a key to their successful development for specific tissue-and tumor-targeting after systemic application (see also Molecular Therapy).Based on the polyplex formulations,...
|
|
|
DTE Energy's $3 Million Investment in QD Vision
TIPS Pentacene, a soluble organic semiconductor for printed and flexible electronics, is manufactured by 3M under the name 3M Organic Electronics Semiconductor L-20856 and is the first in a family of soluble Pentacene-based semiconductors developed by 3M...
|
|
|
Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination wi
- 100% of patients reached target serum urate levels with the combination of RDEA594 and allopurinol - RDEA594 combined with febuxostat reduced serum urate levels in healthy volunteers by approximately 70% SAN DIEGO, Jan.7 /PRNewswire-FirstCall/ --Ardea...
|
|
|
Ardea Biosciences gets positive results for RDEA594 in combo with allopurinol or febuxostat in gout treatment
Ardea Biosciences, Inc announced additional positive results from a recently completed phase-2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from the second panel of a phase-1...
|
|
|
Reverse-Micelle Synthesis of Electrochemically Encoded Quantum Dot Barcodes: Application to Electronic Coding of a Cancer Marker
Reproducible electrochemically encoded quantum dot (QD) barcodes were prepared using the reverse-micelle synthetic approach.The encoding elements, Zn2+, Cd2+, and Pb2+, were confined within a single QD, which eliminates the cumbersome...
|
|
|
Idenix Pharmaceuticals Highlights Progress in Three HCV Programs
CAMBRIDGE, Mass.IDX184: Nucleotide HCV Polymerase Inhibitor The phase II clinical trial, initiated in the fourth quarter of 2009, is a randomized, double-blind, placebo-controlled, sequential dose-escalation study evaluating the safety, tolerability,...
|
|
|
Idenix Pharmaceuticals Highlights Progress in Three HCV Programs
CAMBRIDGE, Mass., Jan.11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three HCV...
|
|
|
Idenix Pharmaceuticals Highlights Progress in Three HCV Programs
6:45 am CAMBRIDGE, Mass., Jan.11 /PRwire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in...
|
|
|
Idenix Pharmaceuticals Highlights Progress in Three HCV Programs
CAMBRIDGE, Mass., Jan.11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three...
|
|
|
Idenix Pharma (IDIX) Announces Progress in Three HCV Programs; Updates on FY09 Guidance
Idenix Pharmaceuticals, Inc.(NASDAQ: IDIX) today announced significant progress in three HCV programs. Idenix will provide a business update on these three HCV development programs and on its partnered programs during a presentation by Jean-Pierre...
|
|
|
Idenix Pharmaceuticals Highlights Progress in Three HCV Programs
- Interim analysis of 50 mg cohort demonstrates potent HCV antiviral activity at 14 days for IDX184, a nucleotide polymerase inhibitor, in combination with PegIFN/Ribavirin - IDX375, a non-nucleoside polymerase inhibitor, exhibited favorable pharmacokinetic...
|
|
|
Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination wi
- 100% of patients reached target serum urate levels with the combination of RDEA594 and allopurinol - RDEA594 combined with febuxostat reduced serum urate levels in healthy volunteers by approximately 70% SAN DIEGO, Jan.7 /PRNewswire-FirstCall/ --Ardea...
|
|
|
Ardea Biosciences reports positive results from gout combination ...
Company: Ardea Biosciences Inc (RDEA) Ardea Biosciences has reported additional positive results from a recently completed Phase IIa study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results...
|
